145 related articles for article (PubMed ID: 10025034)
1. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin.
Boehm S; Nirnberger G; Ferrari P
Wien Klin Wochenschr; 1998 Dec; 110(23):817-23. PubMed ID: 10025034
[TBL] [Abstract][Full Text] [Related]
2. Estrogen reduction by aromatase inhibition for benign prostatic hyperplasia: results of a double-blind, placebo-controlled, randomized clinical trial using two doses of the aromatase-inhibitor atamestane. Atamestane Study Group.
Radlmaier A; Eickenberg HU; Fletcher MS; Fourcade RO; Reis Santos JM; van Aubel OG; Bono AV
Prostate; 1996 Oct; 29(4):199-208. PubMed ID: 8876703
[TBL] [Abstract][Full Text] [Related]
3. [The effects of mepartricin on the symptomatology of prostatic hypertrophy--double-blind controlled trial].
Vanden Bossche M; Abi Aad A; Vandendris M; Van Cangh P; Schulman C
Acta Urol Belg; 1991; 59(1):93-104. PubMed ID: 1718154
[TBL] [Abstract][Full Text] [Related]
4. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
Levine AC; Kirschenbaum A; Gabrilove JL
Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
[TBL] [Abstract][Full Text] [Related]
5. Binding of mepartricin to sex hormones, a key factor of its activity on benign prostatic hyperplasia.
Barone D; Peroglio F; Toso E; Bruzzese T
Arzneimittelforschung; 2001; 51(12):984-90. PubMed ID: 11799846
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic efficacy of mepartricin in the medical treatment of prostatic hypertrophy].
Virgili G; Mearini E; Sbarberi L; Camilli P; Costantini E
Minerva Med; 1986 May; 77(20):861-6. PubMed ID: 2425285
[TBL] [Abstract][Full Text] [Related]
7. [Mepartricin as medical treatment of benign prostatic hypertrophy].
Micali F; Giurioli A; Virgili G; Vespasiani G
J Urol (Paris); 1993; 99(6):293-5. PubMed ID: 7516370
[No Abstract] [Full Text] [Related]
8. [New conservative therapeutic approaches in benign prostatic hyperplasia].
Schulze H; Berges R; Paschold K; Senge T
Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
[TBL] [Abstract][Full Text] [Related]
9. [The role of mepartricin in the medical treatment of benign prostatic adenoma].
Casella G; Barbaro A
Arch Sci Med (Torino); 1978; 135(1):95-8. PubMed ID: 76466
[TBL] [Abstract][Full Text] [Related]
10. Effects of mepartricin on estradiol and testosterone serum levels and on prostatic estrogen, androgen and adrenergic receptor concentrations in adult rats.
Re G; Badino P; Odore R; Vigo D; Bonabello A; Rabino S; Capello F; Bruzzese T
Pharmacol Res; 2001 Aug; 44(2):141-7. PubMed ID: 11516265
[TBL] [Abstract][Full Text] [Related]
11. Study of mepartricin possible interactions with antilipemic drugs. Controlled clinical trials in patients with benign prostatic hyperplasia.
Piccinno A; Cirillo Marucco E; Ludovico GM; Pagliarulo A
Panminerva Med; 1990; 32(3):122-5. PubMed ID: 1706493
[TBL] [Abstract][Full Text] [Related]
12. [Double-blind evaluation of mepartricin 150.000 U (40 mg) compared with placebo in benign prostatic hypertrophy].
Prezioso D; Mirone V; Fabrizio F; Lotti T
Minerva Urol Nefrol; 1996 Dec; 48(4):207-11. PubMed ID: 9005590
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic usefulness of mepartricin in benign prostatic hypertrophy: 2 years' experience. Preliminary note on the effect of mepartricin on certain possible etiopathogenic factors in benign prostatic hypertrophy].
Mirone V; Prezioso D; Palmieri A; Bocchini P
Minerva Urol Nefrol; 1988; 40(2 Suppl):16-7. PubMed ID: 2460938
[No Abstract] [Full Text] [Related]
14. [The effect of mepartricin on prostatic adenoma].
Pellet B; Granata F; von Niederhäusern W
Rev Med Suisse Romande; 1980 Nov; 100(11):899-903. PubMed ID: 6162182
[No Abstract] [Full Text] [Related]
15. Atamestane, a new aromatase inhibitor for the management of benign prostatic hyperplasia.
el Etreby MF; Nishino Y; Habenicht UF; Henderson D
J Androl; 1991; 12(6):403-14. PubMed ID: 1722797
[TBL] [Abstract][Full Text] [Related]
16. Benign prostatic hyperplasia. The Saudi perspective in the year 2000.
Mosli HA; Atwa MA; Mahassini SH
Saudi Med J; 2000 Oct; 21(10):915-20. PubMed ID: 11369951
[TBL] [Abstract][Full Text] [Related]
17. Dutasteride: a dual 5-alpha reductase inhibitor for the treatment of symptomatic benign prostatic hyperplasia.
Dolder CR
Ann Pharmacother; 2006 Apr; 40(4):658-65. PubMed ID: 16569804
[TBL] [Abstract][Full Text] [Related]
18. [Mepartricin 150.000 (40 mg) vs mepartricin 50.000 U (13 mg) in the treatment of BIP. Double blind clinical trial].
Mirone V; Prezioso D; Palmieri A; Lotti T
Minerva Med; 1996 Apr; 87(4):147-54. PubMed ID: 8700338
[TBL] [Abstract][Full Text] [Related]
19. [Non surgical treatment of benign prostatic hypertrophy].
Martini E; Vaggi L; Rucci A; Di Clemente L
J Urol (Paris); 1993; 99(6):278-82. PubMed ID: 7516366
[No Abstract] [Full Text] [Related]
20. [Effect of treatment with mepartricin on the plasma androgen and gonadotropin concentrations in subjects with benign prostatic hypertrophy].
Sciarra F; Bianchi P; Toscano V
Minerva Urol Nefrol; 1988; 40(2 Suppl):10-2. PubMed ID: 2460936
[No Abstract] [Full Text] [Related]
[Next] [New Search]
